Allegra, C, Jessup, JM, Somerfield, MR, et al. American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutati-ons in patients with metastatic colorectal carcinoma to predict res-ponse to anti-epidermal growth factor receptor monoclonal antibody therapy. Journal of Clinical Oncology. 2009;epub JCO.2009.21.9170.
Amado, RG, Wolf, M, Peeters, M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology. 2008;26(10):1626–1634.
Bair, E, Tibshirani, R.Semi-supervised methods to predict patient survival from gene expression data. PLoS Biology. 2004;2:511–522.
Beckman, RA, Clark, J, Chen, C. Integrating predictive biomarkers and classifiers into oncology clinical development programs. Nature Re-views Drug Discovery. 2011;10:735–748.
Ben-Dor, A, Bruhn, L, Friedman, N, Nachman, I, Schummer, M, Yakhini, Z. Tissue classification with gene expression profiles. Journal of Computational Biology. 2000;7:559–584.
Berger, JO. Statistical Decision Theory and Bayesian Analysis. New York: Springer; 2010.
Bo, TH, Jonassen, I.New feature subset selection procedures for classification of expression profiles. Genome Biology. 2002;3(4):0017.1–0017.11.
Bogaerts, J, Cardoso, F, Buyse, M, et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nature Clinical Practice: Oncology. 2006;3(10):540–551.
Bovelstad, HM, Nygard, S, Storvold, HL, et al. Predicting survival from microarray data – a comparative study. Bioinformatics. 2007;23(16):2080–2087.
Cai, T, Tian, L, Wong, PH, Wei, LJ. Analysis of randomized comparative clinical trial data for personalized treatment selections. Biostatistics. 2011;12:270–282.
Cook, NR.Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115(7):928–935.
Cox, DR.Regression models and life-tables. Journal of the Royal Statistical Society B. 1972;34:187–220.
Cox, DR, Snell, EJAnalysis of Binary Data. Boca Raton FL, Chapman and Hall/CRC; 1989.
Cronin, M, Sangli, C, Liu, M-L, et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clinical Chemistry. 2007;53(6):1084–1091.
Crowley, J, Hoering, A eds. Handbook of Statistics in Clinical Oncology, 3rd ed. Boca Raton, FL: Chapman Hall/CRC; 2012.
Deutsch, JM. Evolutionary algorithms for finding optimal gene sets in microarray prediction. Bioinformatics. 2003;19:45–54.
Dobbin, K, Simon, R.Sample size determination in microarray experiments for class comparison and prognostic classification. Biostatistics. 2005;6:27–38.
Dobbin, K, Simon, R. Sample size planning for developing classifiers using high dimensional DNA expression data. Biostatistics. 2007;8:101–117.
Dobbin, K, Simon, ROptimally splitting cases for training and testing high dimensional classifiers. BMC Medical Genomics. 2011;4:31.
Dobbin, KK, Zhao, Y, Simon, RM. How large a training set is needed to develop a classifier for microarray data?Clinical Cancer Research. 2008;14:108–114.
Dudoit, S, Fridlyand, J. Classification in microarray experiments. In: Speed, T, ed. Statistical Analysis of Gene Expression Microarray Data. Boca Raton, FL: Chapman and Hall/CRC; 2003:93–158.
Dudoit, S, Fridlyand, J, Speed, TP. Comparison of discrimination methods for the classification of tumors using gene expression data. Journal of the American Statistical Association. 2002;97:77–87.
Dupuy, A, Simon, R. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. Journal of the National Cancer Institute. 2007;99:147–157.
Ellenberg, S, Fleming, TR, DeMets, D. Data Monitoring Committees in Clinical Trials: A Practical Perspective. New York: Wiley; 2002.
Fisher, RA. The use of multiple measurements in taxonomic problems. Annals of Eugenics. 1936;7:179–188.
Fleming, TR.Interpretation of subgroup analyses in clinical trials. Drug Information Journal. 1995;29:1681S–1687S.
Fleming, TR, Watelet, L. Approaches to monitoring clinical trials. Journal of the National Cancer Institute. 1989;188–193.
Foster, JC, Taylor, JMG, Ruberg, SJ. Subgroup identification from randomized clinical trial data. Statistics in Medicine. 2011;30:2867–2880.
Fox, E, Curt, GA, Balis, FM. Clinical trial design for target-based therapy. The Oncologist 2002;7:401–409.
Freidlin, B, Jiang, W, Simon, R. The cross-validated adaptive signature design for predictive analysis of clinical trials. Clinical Cancer Research. 2010;16(2):691–698.
Freidlin, B, McShane, LM, Korn, EL. Randomized clinical trials with biomarkers: design issues. Journal of the National Cancer Institute. 2010;102(3):152–160.
Freidlin, B, Simon, R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clinical Cancer Research. 2005;11:7872–7878.
Freidlin, B, McShane, LM, Polley, MY, Korn, EL. Randomized phase II trial designs with biomarkers. Journal of Clinical Oncology. 2012;30(30):3304–3309.
Golub, TR, Slonim, DK, Tamayo, P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531–537.
Green, S, Benedetti, J, Crowley, J.Clinical Trials in Oncology. 2nd ed. Boca Raton FL: Chapman and Hall/CRC; 2003.
Harrell, FE. Regression Modeling Strategies with Applications to Linear Models, Logistic Regression and Survival Analysis. New York: Springer; 2001.
Hastie, T, Tibshirani, R, Eisen, M, et al. Gene shaving as a method for identifying distinct sets of genes with similar expression patterns. Genome Biology. 2000;1(2)3.1–3.21.
Hastie, T, Tibshirani, R, Friedman, J.The Elements of Statistical Learning: Data Mining, Inference, and Prediction, 2nd ed. New York: Springer; 2009.
Haybittle, JL.Repeated assessment of results in clinical trials of cancer treatment. Journal of Radiology. 1971;44:793.
Hayes, DF, Bast, RC, Desch, CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. Journal of the National Cancer Institute. 1996;88:1456–1466.
Heagerty, PJ, Lumley, T, Pepe, MS. Time dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337–344.
Hess, KR, Anderson, K, Symmans, WF, et al. Pharmacogenomic predictor of sensitivity to preoperative paclitaxel and 5-flurouracil, doxorubicin, cyclophosphamide chemotherapy in breast cancer. Journal of Clinical Oncology. 2006;24(26):4236–4244.
Hoering, A, LeBlanc, M, Crowley, JJ.Randomized phase III clinical trial designs for targeted agents. Clinical Cancer Research. 2008;14:4358–4367.
Hsieh, FY, Lavori, PW. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates, Controlled Clinical Trials. 2000;21:552–560.
Hunsberger, S, Zhao, Y, Simon, R. A comparison of phase II study strategies. Clinical Cancer Research. 2009;15(19):5950–5955.
Jennison, C, Turnbull, BW. Group Sequential Methods with Applications to Clinical Trials. Boca Raton, FL: Chapman and Hall; 1999.
Jiang, W, Freidlin, B, Simon, R. Biomarker adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. Journal of the National Cancer Institute. 2007;99:1036–1043.
Jones, CL, Holmgren, E. An adaptive Simon two-stage design for phase 2 studies of targeted therapies. Contemporary Clinical Trials. 2007;28:654–666.
Kalbfleisch, JD, Prentice, RL. The Statistical Analysis of Failure Time Data. New York: Wiley; 2002.
Kaplan, EI, Meier, P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association. 1958;53:457–481.
Karapetis, CS, Khambata-Ford, S, Jonker, DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New England Journal of Medicine. 2008;359(17):1757–1765.
Karuri, S, Simon, R. A two-stage Bayesian design for co-development of new drugs and companion diagnostics. Statistics in Medicine. 2012;31(10):901–914.
Kattan, MW. Judging new markers by their ability to improve predictive accuracy. Journal of the National Cancer Institute. 2003;95(9):634–635.
Kattan, MW. Evaluating a new marker's predictive contribution. Clinical Cancer Research. 2004;10:822–824.
Khan, J, Wei, JS, Ringner, M, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nature Medicine. 2001;7:673–679.
Kim, KI, Simon, R. Probabilistic classifiers with high dimensional data. Biostatistics. 2011;12(3):399–412.
Korn, EL, Freidlin, B. Outcome-adaptive randomization: is it useful?Journal of Clinical Oncology. 2011;29:771–776.
Korn, EL, Freidlin, B, Abrams, JS, Halabi, S. Design issues in randomized phase II/III trials. Journal of Clinical Oncology. 2012;30(6):667–671.
Lai, TL, Lavori, PW, Shih, M, Sikic, BI. Clinical trial designs for testing biomarker-based personalized therapies. Clinical Trials. 2012;9:141–154.
Lai, C, Reindders, MJT, van't Veer, LJ, Wessels, LFA. A comparison of univariate and multivariate gene selection techniques for classification of cancer datasets. BMC Bioinformatics. 2006;7:235.
Lenz, G, Wright, GW, Dave, SS, et al. Stromal gene signatures in large-B-cell lymphomas. New England Journal of Medicine. 2008;359(22):2313–2323.
Li, H, Gui, J. Partial Cox regression analysis for high-dimensional microarray gene expression data. Bioinformatics. 2004;20:i208–i215.
Liu, A, Li, Q, Yu, KF, Yuan, VW. A threshold sample-enrichment approach in a clinical trial with heterogeneous subpopulations. Clinical Trials. 2010;7(5):537–545.
Maitournam, A, Simon, ROn the efficiency of targeted clinical trials. Statistics in Medicine. 2005;24:329–339.
Mandrekar, SJ, Sargent, DJ. Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. Journal of Clinical Oncology. 2009;27:4027–4034.
Mandrekar, SJ, Sargent, DJ. Predictive biomarker validation in practice: lessons from real trials. Clinical Trials. 2010;7:567–573.
Mantel, N.Chi-square tests with one degree of freedom; extensions of the Mantel-Haenszel procedure. Journal of American Statistical Association. 1963;58:690–700.
Marubini, E, Valsecchi, MG. Analysing Survival Data from Clinical Trials and Observational Studies. New York: Wiley; 1995.
Matsui, S, Simon, R, Qu, P, Shaughnessy, JD, Barlogie, B, Crowley, JJ. Developing and validating continuous genomic signatures in randomized clinical trials for predictive medicine. Clinical Cancer Research. 2012; 18(21):6065--6073.
McShane, LM, Hunsberger, S, Adjei, AA. Effective incorporation of bio-markers into phase II trials. Clinical Cancer Research. 2009;15(6):1898–1905.
Molinaro, AM, Simon, R, Pfeiffer, RM. Prediction error estimation: a comparison of resampling methods. Bioinformatics. 2005;21(15):3301–3307.
Nguyen, DV, Rocke, DM. Partial least squares proportional hazard regression for application to DNA microarray survival data. Bioinformatics. 2002;18:1625–1632.
O’Brien, PC, Fleming, TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549–556.
Ooi, CH, Tan, P. Genetic algorithms applied to multi-class prediction for the analysis of gene expression data. Bioinformatics. 2003;19:37–44.
Paik, S, Shak, S, Tang, G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine. 2004;351:2817–2826.
Park, PJ, Tian, L, Kohane, IS. Linking gene expression data with patient survival times using partial least squares. Bioinformatics. 2002;18:S120–S127.
Pepe, MS. The Statistical Evaluation of Medical Tests for Classification and Prediction. New York: Oxford University Press; 2004.
Pepe, MS, Janes, H, Longton, G, Leisenring, W, Newcomb, P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic or screening marker. American Journal of Epidemiology. 2004;159:882–890.
Pepe, MS, Feng, Z, Janes, H, Bossuyt, PM, Potter, JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: Standards for study design. Journal of the National Cancer Institute. 2008;100(20):1432–1438.
Peterson, B, George, SL. Sample size requirements and length of study for testing interaction in a 1 × k factorial design when time-to-failure is the outcome. Controlled Clinical Trials. 1993;14:511–522.
Peto, R, Pike, MC, Armitage, P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II Analysis and examples. British Journal of Cancer. 1977;35:1–39.
Piantadosi, S. Clinical Trials: A Methodologic Perspective. New York, Wiley; 2005.
Pocock, SJ. Interim analyses for randomized clinical trials. Biometrics. 1982;39:153.
Pocock, SJ, Assmann, SE, Enos, LE, Kasten, LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Statistics in Medicine. 2002;21:2917–2930.
Pusztai, L.Perspectives and challenges of clinical pharmacogenomics in cancer. Pharmacogenomics. 2004;5(5):451–454.
Pusztai, L, Anderson, K, Hess, KR. Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer. Clinical Cancer Research. 2007;13:6080–6086.
Radmacher, MD, McShane, LM, Simon, R. A paradigm for class prediction using gene expression profiles. Journal of Computational Biology. 2002;9:505–512.
Rosenwald, A, Wright, G, Chan, WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New England Journal of Medicine. 2002;346:1937–1947.
Rubin, DB. Bayesian Data Analysis. Boca Raton FL, Chapman and Hall/CRC; 2009.
Rubin, DB, van der Laan, MJ. Statistical issues and limitations in personalized medicine research with clinical trials. The International Journal of Biostatistics. 2012;8:1–37.
Sargent, DJ, Conley, BA, Allegra, C, Collette, L. Clinical trial designs for predictive marker validation in cancer treatment trials. Journal of Clinical Oncology. 2005;23(9):2020–2027.
Sawyers, CL. The cancer biomarker problem. Nature. 2008;452:548–552.
Shedden, K, Taylor, JMG, Enkemann, SA, et al. Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nature Medicine. 2008;14(8):822–827.
Sher, HI, Nasso, SF, Rubin, E, Simon, R. Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics. Clinical Cancer Research. 2011;17:6134–6140.
Simon, R.Confidence intervals for reporting results from clinical trials. Annals of Internal Medicine. 1986;105:429–435.
Simon, R.Optimal two-stage design for phase II clinical trials. Controlled Clinical Trials. 1989;10:1–10.
Simon, RM, Korn, EL, McShane, LM, et al. Design and Analysis of DNA Microarray Investigations. New York: Springer; 2004.
Simon, R, Lam, A, Li, MC, Ngan, M, Menezes, S, Zhao, Y. Analysis of gene expression data using BRB-ArrayTools. Cancer Informatics. 2007;2:11–17.
Simon, R.Using genomics in clinical trial design. Clinical Cancer Research. 2008b;14:5984–5993.
Simon, R.Design and analysis of clinical trials. In: DeVita, VT, DePinto, RA, Lawrence, TS, Rosenberg, SA, Weinberg, RA, eds. Principles and Practice of Oncology. 9th ed. Philadelphia: Lippincott, Williams, and Wilkins; 2011:Chapter 70.
Simon, R. Clinical trials for predictive medicine. Statistics in Medicine. In press.
Simon, R, Maitournam, A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clinical Cancer Research. 2005;10:6759–6763.
Simon, R, Maitournam, A. Evaluating the efficiency of targeted designs for randomized clinical trials: supplement and correction. Clinical Cancer Research. 2006;12:3229.
Simon, RM, Paik, S, Hayes, DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. Journal of the National Cancer Institute. 2009;101(21):1–7.
Simon, R, Radmacher, MD, Dobbin, K, McShane, LM. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. Journal of the National Cancer Institute. 2003;95:14–18.
Simon, RM, Subramanian, J, Li, MC, Menezes, S. Using cross validation to evaluate prediction accuracy of survival risk classifiers based on high dimensional data. Briefings in Bioinformatics. 2011;12(3):203–214.
Simon, R, Wang, SJ. Use of genomic signatures in therapeutics development. The Pharmacogenomics Journal. 2006;6:1667–1173.
Slamon, DJ, Leyland-Jones, B, Shak, S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine. 2001;344(11):783–792.
Smith, M, Ungerleider, R, Korn, E, Rubinstein, L, Simon, R. The role of independent data monitoring committees in randomized clinical trials sponsored by the National Cancer Institute. Journal of Clinical Oncology. 1997;15:2736–2743.
Song, Y, Chi, GYH. A method for testing a prespecified subgroup in clinical trials. Statistics in Medicine. 2007;26:3535–3549.
Sparano, JA, Paik, S. Development of the 21-gene assay and its application in clinical practice and clinical trials. Journal of Clinical Oncology. 2008;26(5):721–728.
Speed, T, ed. Statistical Analysis of Gene Expression Microarray Data. Boca Raton, FL: Chapman and Hall/CRC; 2003.
Spiegelhalter, DJ, Freedman, LS, Parmar, MKB. Bayesian approaches to randomized trials. Journal of the Royal Statistical Society A. 1994;157:357–387.
Subramanian, J, Simon, R. An evaluation of resampling methods for assessment of survival risk prediction in high dimensional settings. Statistics in Medicine. 2011;30(6):642–653.
Subramanian, J, Simon, R. Gene expression-based prognostic signatures in lung cancer: Ready for clinical use?Journal of the National Cancer Institute. 2010a;102:464–474.
Subramanian, J, Simon, R.What should physician look for in evaluating prognostic gene expression signatures. Nature Reviews Clinical Oncology. 2010b;7:327–334.
Taylor, JMG, Ankerst, DP, Andridge, RR. Validation in biomarker based risk prediction models. Clinical Cancer Research. 2008;14:5977–5983.
Tibshirani, R.The lasso method for variable selection in the Cox model. Statistics in Medicine. 1997;16:385–395.
Tibshirani, R, Hastie, T, Narasimhan, B, et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proceedings of the National Academy of Sciences of the United States of America. 2002;99:6567–6572.
van-de-Vijver, MJ, He, YD, Veer, LJvt, et al. A gene expression signature as a predictor of survival in breast cancer. New England Journal of Medicine. 2002;347(25):1999–2009.
vanHouwelingen, HC, Bruinsma, T, Hart, AAM, van'tVeer, LJ, Wessels, LFA. Cross-validated Cox regression on microarray gene expression data. Statistics in Medicine. 2006;25:3201–3216.
van't-Veer, LJ, Dai, H, Vijver, MJvd, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536.
vanWieringen, WN, Kun, D, Hampel, R, Boulesteix, AL. Survival prediction using gene expression data: a review and comparison. Computational Statistics and Data Analysis. 2009;53:1590–1603.
Varma, S, Simon, R. Bias in error estimation when using cross-validation for model selection. BMC Bioinformatics. 2006;7:91.
Wang, SJ, O’Neill, RT, Hung, HMJ. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics. 2007;6:227–244.
West, M, Blanchette, C, Dressman, H. Predicting the clinical status of human breast cancer by using gene expression profiles. Proceedings of the National Academy of Sciences of the United States of America. 2001;98:11462–11467.
Zhang, B, Tsiatis, AA, Laber, EB, Davidian, M.A robust method for estimating optimal treatment regimens. Biometrics 2012 (Online May 2, 2012).
Zhao, YD, Dmitrienko, A, Tamura, R. On optimal designs of clinical trials with a sensitive subgroup. Statistics in Biopharmaceutical Research. 2010;2(1):72–83.
